Motley Fool Money Are psychedelics investable?
Apr 13, 2022
Jason Moser, a senior analyst at Motley Fool, discusses the recent earnings of JPMorgan Chase amid economic trends. Meanwhile, Meilin Quinn, an expert in the psychedelic industry, dives into its regulatory challenges and investment opportunities. They debate the parallels between psychedelics and the cannabis market, emphasizing the caution needed in this emerging sector. As mental health treatments gain attention, Quinn highlights both the optimism and skepticism investors should consider before diving into this intriguing market.
AI Snips
Chapters
Transcript
Episode notes
Psychedelic Studies
- Investing in psychedelics for mental health raises questions about conducting double-blind studies.
- It's difficult to maintain a true double-blind setup when the drug's effects are obvious.
Psychedelic Investment Trend
- Investors are increasingly interested in psychedelics due to growing awareness and perceived mental health benefits.
- Over 80 companies are now researching or developing psychedelic compounds, fueled by cultural trends and investments.
Regulatory Challenges
- Most psychedelics are Schedule I drugs with strict regulations, making widespread adoption challenging.
- This differs from cannabis, where CBD-based Epidiolex gained approval due to lower abuse potential.